• 1.

    Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684–H1689.

    • Search Google Scholar
    • Export Citation
  • 2.

    Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007;9:787794.

    • Search Google Scholar
    • Export Citation
  • 3.

    Goetze JP, Rehfeld JF, Videbaek R, et al. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. Eur J Heart Fail 2005;7:6974.

    • Search Google Scholar
    • Export Citation
  • 4.

    Chen HH, Grantham JA, Schirger JA, et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000;36:17061712.

    • Search Google Scholar
    • Export Citation
  • 5.

    Lainchbury JG, Burnett JC Jr, Meyer D, et al. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000;278:H33H40.

    • Search Google Scholar
    • Export Citation
  • 6.

    Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases (Erratum published in Congest Heart Fail 2005;11:102). Congest Heart Fail 2004;10(5 suppl 3):130.

    • Search Google Scholar
    • Export Citation
  • 7.

    Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:17331739.

    • Search Google Scholar
    • Export Citation
  • 8.

    Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:2145.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cardarelli R, Lumicao TG Jr. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003;16:327333.

    • Search Google Scholar
    • Export Citation
  • 10.

    Mueller C, Breidthardt T, Laule-Kilian K, et al. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007;137:412.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hutcheon SD, Gillespie ND, Struthers AD, et al. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing 2002;31:295301.

    • Search Google Scholar
    • Export Citation
  • 12.

    Takase H, Toriyama T, Sugiura T, et al. Brain natriuretic peptide detects cardiac abnormalities in mass screening. Eur J Clin Invest 2007;37:257262.

    • Search Google Scholar
    • Export Citation
  • 13.

    Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:11151140.

    • Search Google Scholar
    • Export Citation
  • 14.

    Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523529.

    • Search Google Scholar
    • Export Citation
  • 15.

    MacDonald KA, Kittleson MD, Munro C, et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003;17:172177.

    • Search Google Scholar
    • Export Citation
  • 16.

    Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res 2007;68:4247.

    • Search Google Scholar
    • Export Citation
  • 17.

    DeFrancesco TC, Rush JE, Rozanski EA, et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007;21:243250.

    • Search Google Scholar
    • Export Citation
  • 18.

    Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287296.

    • Search Google Scholar
    • Export Citation
  • 19.

    Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT–proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330337.

    • Search Google Scholar
    • Export Citation
  • 20.

    Mueller T, Gegenhuber A, Poelz W, et al. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:4148.

    • Search Google Scholar
    • Export Citation
  • 21.

    Alibay Y, Beauchet A, El Mahmoud R, et al. Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. Clin Biochem 2004;37:933936.

    • Search Google Scholar
    • Export Citation
  • 22.

    Mueller T, Gegenhuber A, Poelz W, et al. Biochemical diagnosis of impaired left ventricular ejection fraction—comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004;42:159163.

    • Search Google Scholar
    • Export Citation
  • 23.

    Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: 10721083.

    • Search Google Scholar
    • Export Citation
  • 24.

    Hansson K, Haggstrom J, Kvart C, et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568575.

    • Search Google Scholar
    • Export Citation
  • 25.

    Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.

  • 26.

    Hansson K, Haggstrom J, Kvart C, et al. Interobserver variability of vertebral heart size measurements in dogs with normal and enlarged hearts. Vet Radiol Ultrasound 2005;46:122130.

    • Search Google Scholar
    • Export Citation
  • 27.

    Lamb CR, Wikeley H, Boswood A, et al. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001;148:707711.

    • Search Google Scholar
    • Export Citation
  • 28.

    International Small Animal Cardiac Health Council. Appendix A: recommendations for diagnosis of heart disease and treatment of heart failure in small animals. In: Fox PR, Sisson DD, Moise NS, eds. Textbook of canine and feline cardiology. 2nd ed. Philadelphia: WB Saunders Co, 1999;883901.

    • Search Google Scholar
    • Export Citation
  • 29.

    Metra M, Nodari S, Parrinello G, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007;9:776786.

    • Search Google Scholar
    • Export Citation
  • 30.

    van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:386390.

    • Search Google Scholar
    • Export Citation
  • 31.

    O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:5055.

    • Search Google Scholar
    • Export Citation
  • 32.

    Abdulle AM, Nagelkerke NJ, Adem A, et al. Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population. J Hum Hypertens 2007;21:647653.

    • Search Google Scholar
    • Export Citation
  • 33.

    Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745751.

    • Search Google Scholar
    • Export Citation
  • 34.

    Eriksson AS, Järvinen AK, Eklund KK, et al. Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles spaniels. Am J Vet Res 2001;62:18181824.

    • Search Google Scholar
    • Export Citation
  • 35.

    Baumwart RD, Meurs KM. Assessment of plasma brain natriuretic peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2005;66:20862089.

    • Search Google Scholar
    • Export Citation

Advertisement

Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity

Mark A. Oyama DVM, DACVIM1, Philip R. Fox DVM, DACVECC, DACVIM2, John E. Rush DVM, MS, DACVECC, DACVIM3, Elizabeth A. Rozanski DVM, DACVIM, DACVECC4, and Mike Lesser DVM, DACVIM5
View More View Less
  • 1 Department of Veterinary Clinical Studies—Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104
  • | 2 Animal Medical Center, 510 E 62nd St, New York, NY 10065
  • | 3 Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536
  • | 4 Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536
  • | 5 Advanced Veterinary Care Center, 15926 Hawthorne Blvd, Lawndale, CA 90260

Abstract

Objective—To determine whether serum N-terminal pro-B-type natriuretic (NT-proBNP) concentration could be used to identify cardiac disease in dogs and to assess disease severity in affected dogs.

Design—Cross-sectional study.

Animals—119 dogs with mitral valve disease, 18 dogs with dilated cardiomyopathy, and 40 healthy control dogs.

Procedures—Serum NT-proBNP concentration was measured with an ELISA validated for use in dogs. Results of physical examination, thoracic radiography, echocardiography, and serum biochemical analyses were recorded for dogs with cardiac disease.

Results—Serum NT-proBNP concentration was significantly higher in dogs with cardiac disease than in control dogs, and a serum NT-proBNP concentration > 445 pmol/L could be used to discriminate dogs with cardiac disease from control dogs with a sensitivity of 83.2% and specificity of 90.0%. In dogs with cardiac disease, serum NT-proBNP concentration was correlated with heart rate, respiratory rate, echocardiographic heart size, and renal function. For dogs with cardiac disease, serum NT-proBNP concentration could be used to discriminate dogs with and without radiographic evidence of cardiomegaly and dogs with and without congestive heart failure.

Conclusions and Clinical Relevance—Results suggested that serum NT-proBNP concentration may be a useful adjunct clinical test for diagnosing cardiac disease in dogs and assessing the severity of disease in dogs with cardiac disease.

Contributor Notes

Drs. Oyama, Fox, and Rush consult for Veterinary Diagnostics Institute, Irvine, Calif.

Supported by a research grant from Veterinary Diagnostics Institute, Irvine, Calif.

The authors thank Drs. Meg Sleeper, Steve Cole, Nick Russell, Jason Arndt, Ellen Davison, Caryn Reynolds, J. P. Petrie, Elizabeth Cole, Betsy Bond, Suzanne Cunningham, Sarah Miller, and Sarah Zimmerman for patient recruitment and Carolyn Michel, Fe Wright, Barbara Brewer, and Mary Perricone for technical assistance.

Address correspondence to Dr. Oyama.